Elekta forks over $28.5M for Resonant Medical

Sweden's Elekta has purchased all outstanding shares of Resonant Medical (RMI), a Montreal-based image guided radiation therapy (IGRT) company with 35 employees, for $28.5 million. The company is developing systems for IGRT of soft tissues using 3-D ultrasound technology, which improves treatment accuracy for cancer in the prostate, breast, liver, cervix, uterus, bladder as well as head and neck. Elekta says the buyout will give the company access to image guidance solution and RMI's R&D resources in oncology imaging and motion management.

"This is really exciting, as it further enhances Elekta's state-of-the-art solutions in IGRT, by adding RMI's leadership in soft tissue visualization and tracking, especially focused on innovative solutions for breast and prostate cancer," says Elekta's President and CEO Tomas Puusepp in a statement. "In addition, given Elekta's dedication to open architecture, the technology will be made available to customers with other vendors' equipment, making it possible to improve IGRT processes everywhere."

- here's Elekta's release
- read the Health Imaging and IT piece for more

Suggested Articles

The clinical testing giant LabCorp will now begin rolling out a blood test for lung cancer developed by Resolution Bioscience.

Cognoa aims to equip pediatricians with an AI-powered app that can spot the signs of autism, allowing them to diagnose in the doctor's office.

Longitude Capital invests in what its founders call “transformative healthcare companies," working in areas they hope will increase quality of life.